Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetRevenue - OtherShares IssuedShares OutstandingShares Outstanding
Ratios

Cartesian Therapeutics (RNAC) Leases (2018 - 2026)

Cartesian Therapeutics (RNAC) has disclosed Leases for 9 consecutive years, with $5.4 million as the latest value for Q1 2026.

  • For Q1 2026, Leases changed 0.28% year-over-year to $5.4 million; the TTM value through Mar 2026 reached $5.4 million, changed 0.28%, while the annual FY2025 figure was $5.6 million, 1.19% up from the prior year.
  • Leases hit $5.4 million in Q1 2026 for Cartesian Therapeutics, down from $5.6 million in the prior quarter.
  • Across five years, Leases topped out at $13.9 million in Q2 2024 and bottomed at $3.2 million in Q4 2022.
  • Average Leases over 5 years is $8.5 million, with a median of $9.5 million recorded in 2022.
  • Year-over-year, Leases tumbled 67.44% in 2022 and then surged 214.63% in 2023.
  • Cartesian Therapeutics' Leases stood at $3.2 million in 2022, then soared by 214.63% to $10.1 million in 2023, then plummeted by 45.02% to $5.5 million in 2024, then rose by 1.19% to $5.6 million in 2025, then fell by 4.2% to $5.4 million in 2026.
  • According to Business Quant data, Leases over the past three periods came in at $5.4 million, $5.6 million, and $5.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.